Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Eliezer M. Van Allen1,2, Kent W. Mouw3,4, Philip Kim5, Gopa Iyer6,7, Nikhil Wagle1,2, Hikmat Al-Ahmadi8,8, Cong Zhu2, Irina Ostrovnya9, Gregory V. Kryukov2, Kevin W. O’Connor2, John Sfakianos5, Ilana Garcia-Grossman7, Jaegil Kim2, Elizabeth A. Guancial10, Richard Bambury7, Samira Bahl2, Namrata Gupta2, Deborah Farlow2, Angela Qu1, Sabina Signoretti11, Justine A. Barletta11, Victor Reuter6,8, Jesse Boehm2, Michael Lawrence2, Gad Getz2,12, Philip Kantoff1, Bernard H. Bochner5,6, Toni K. Choueiri1, Dean F. Bajorina6,7, David B. Soltis5,7,13, Stacey Gabriel1, Alan D’Andrea3,4, Levi A. Garraway1,2, and Jonathan E. Rosenberg6,7

ABSTRACT

Cisplatin-based chemotherapy is the standard of care for patients with muscle-invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely understood. We performed whole-exome sequencing on pre-treatment tumor and germline DNA from 50 patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy (25 pT0/pTis “responders” vs 25 pT2+ “nonresponders”) to identify somatic mutations that occurred preferentially in responders. ERCC2, a nucleotide excision repair gene, was the only significantly mutated gene enriched in the cisplatin responders compared with nonresponders (q < 0.01). Expression of representative ERCC2 mutants in an ERCC2-deficient cell line failed to rescue cisplatin and UV sensitivity compared with wild-type ERCC2. The lack of normal ERCC2 function may contribute to cisplatin sensitivity in urothelial cancer, and somatic ERCC2 mutation status may inform cisplatin-containing regimen usage in muscle-invasive urothelial carcinoma.

INTRODUCTION

Platinum-based chemotherapy has been the standard of care for patients with muscle-invasive and metastatic urothelial carcinoma for more than 20 years (1–3), and neoadjuvant cisplatin-based chemotherapy leads to a 14% to 25% relative risk reduction for death from muscle-invasive urothelial carcinoma (cT2-T4aN0M0; refs. 3–5). Pathologic downstaging to complete response (pT0) or carcinoma in situ (pTis) at cystectomy occurs in 26% to 38% of patients treated with neoadjuvant chemotherapy compared with 12.3% to 15% for patients undergoing cystectomy alone (3, 4, 6). The 5-year survival for pT0/pTis patients is 85% after neoadjuvant chemotherapy (3) compared with 43% for patients with persistent muscle-invasive disease (≥pT2; ref. 7). Therefore, the benefit of neoadjuvant chemotherapy seems to be most dramatic in patients who are found to have pathologic complete responses at the time of surgical resection. However, the inability to predict which patients will derive clinical benefit has limited the use of this toxic approach in the urologic community (8–10).

Cisplatin causes accumulation of DNA cross-links, which interfere with DNA replication and gene transcription, and eventually promotes cell death. Repair of cisplatin-induced DNA damage occurs primarily through DNA repair pathways such as nucleotide excision repair (NER; ref. 11) and homologous recombination (which includes BRCA1 and BRCA2; ref. 12). The NER pathway involves multiple genes, including ERCC1–5, CDK7, DDB1–2, XPA, and XPC (13). Germline alterations in NER genes result in multiple recessive inherited disorders, including xeroderma pigmentosum (XP; ref. 13). Because of a deficiency in NER, patients with XP have significantly increased risk of developing skin cancers and other malignancies (14).

Germline or expression-based changes in several NER genes have been suggested to modulate clinical response to cisplatin-based chemotherapy (15, 16). However, prospective studies have not confirmed these observations (17, 18). ERCC2 (an NER helicase) loss-of-function correlates with cisplatin sensitivity in preclinical models (19), whereas ERCC2 overexpression leads to cisplatin resistance (20). These data suggest that tumors with loss of NER function may exhibit increased cisplatin sensitivity, and recent data have identified somatic ERCC2 mutations in 7% to 12% of urothelial carcinomas (21, 22). We hypothesized that somatic mutations in the NER pathway may correlate with response to cisplatin-based neoadjuvant chemotherapy in patients with urothelial carcinoma. To test this, and more generally to define genomic correlates of chemotherapy response, we performed whole-exome sequencing (WES) of urothelial...
RESULTS
Somatic Genetic Alterations in Muscle-Invasive Urothelial Carcinoma

We sequenced pretreatment tumor and germline DNA from 50 patients treated with neoadjuvant cisplatin-based chemotherapy for muscle-invasive urothelial carcinoma; 25 “responders” had no residual muscle-invasive (pT0/pTis) disease at pathologic examination following cystectomy, and 25 “nonresponders” had residual muscle-invasive (pT2) disease (Fig. 1A; Methods). Although multiple chemotherapeutic regimens were used, the only common agent among all patients was cisplatin (Table 1 and Supplementary Table S1). No significant differences in clinical characteristics were identified between responders and nonresponders at baseline (P > 0.05; Mann–Whitney test).

The mean target coverage from WES was 121× for tumors and 130× for paired germline samples (Supplementary Table S1). The median mutation rate was 9.7 mutations per Mb for tumors (n = 50 patients) demonstrates a set of statistically significant genes that are altered in urothelial carcinoma (TP53, RB1, KDM6A, and ARID1A). The negative log of the q-values for the significance level of mutated genes is shown (for all genes with q < 0.1) on the right. ERCC2 mutation status is also shown below the other genes, although ERCC2 was not significantly mutated across the combined cohort. Additional data about allelic fraction ranges for each case (bottom), mutation rates (top), and mutational frequency (left) are also summarized.
nonresponders nominated four significantly altered genes previously implicated in urothelial carcinoma (21, 22, 24): TP53, RB1, KDM6A, and ARID1A (Fig. 1B and Supplementary Tables S3 and S4). In addition, nine nonsynonymous somatic mutations were observed in ERCC2 (Fig. 1B; Supplementary Fig. S2; Supplementary Table S2). Although ERCC2 did not reach cohort-wide statistical significance, its known role in DNA repair and report of being recurrently mutated in bladder cancer (21, 22) raised the possibility that ERCC2 mutations might associate with cisplatin response.

Somatic ERCC2 Mutations in Cisplatin-Based Chemotherapy Responders

We performed an enrichment analysis to identify genes that were selectively mutated in the responders compared with nonresponders (Supplementary Methods). Among 3,277 genes with at least one possibly damaging somatic alteration (Supplementary Methods), ERCC2 was the only gene significantly enriched in the responder cohort (Fig. 2A and Supplementary Tables S5 and S6). Indeed, all ERCC2 nonsynonymous somatic mutations in cisplatin-based chemotherapy responders are listed in Table 1.

Table 1. Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total (N = 50)</th>
<th>Responders (n = 25)</th>
<th>Nonresponders (n = 25)</th>
<th>P &gt; 0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at TUR, y</td>
<td>62.5 ± 8.9</td>
<td>61 ± 10.1</td>
<td>64 ± 7.3</td>
<td>P &gt; 0.05</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>13 (26)</td>
<td>6 (24)</td>
<td>7 (28)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>1 (4)</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic/non-Latino</td>
<td>48 (96)</td>
<td>24 (96)</td>
<td>24 (96)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (2)</td>
<td>1 (4)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>49 (98)</td>
<td>25 (100)</td>
<td>24 (96)</td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>1 (4)</td>
<td></td>
</tr>
<tr>
<td>Smoking status, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>13 (26)</td>
<td>8 (32)</td>
<td>5 (20)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>26 (52)</td>
<td>13 (52)</td>
<td>13 (52)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>11 (22)</td>
<td>4 (16)</td>
<td>7 (28)</td>
<td></td>
</tr>
<tr>
<td>Clinical staging, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>37 (74)</td>
<td>19 (76)</td>
<td>18 (72)</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>10 (20)</td>
<td>5 (20)</td>
<td>5 (20)</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>3 (6)</td>
<td>1 (4)</td>
<td>2 (8)</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>40 (80)</td>
<td>18 (72)</td>
<td>22 (88)</td>
<td></td>
</tr>
<tr>
<td>Node positive</td>
<td>10 (20)</td>
<td>7 (28)</td>
<td>3 (12)</td>
<td></td>
</tr>
<tr>
<td>TUR histology, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCC</td>
<td>32 (64)</td>
<td>19 (76)</td>
<td>13 (52)</td>
<td></td>
</tr>
<tr>
<td>Mixed TCC</td>
<td>18 (36)</td>
<td>6 (24)</td>
<td>12 (48)</td>
<td></td>
</tr>
<tr>
<td>Neoadjuvant chemotherapy regimen, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GC</td>
<td>31 (62)</td>
<td>14 (56)</td>
<td>17 (68)</td>
<td></td>
</tr>
<tr>
<td>ddMVAC</td>
<td>16 (32)</td>
<td>9 (36)</td>
<td>7 (28)</td>
<td></td>
</tr>
<tr>
<td>GC-sunitinib</td>
<td>2 (4)</td>
<td>2 (8)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>ddGC</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>1 (4)</td>
<td></td>
</tr>
<tr>
<td>Median interval from chemotherapy to cystectomy (days ± SD)</td>
<td>47 ± 29.9</td>
<td>46 ± 26.0</td>
<td>47 ± 33.8</td>
<td>P &gt; 0.05</td>
</tr>
<tr>
<td>Median length of follow-up (days ± SD)*</td>
<td>351 ± 363.2</td>
<td>372.5 ± 416.2</td>
<td>329.5 ± 287.1</td>
<td>P &gt; 0.05</td>
</tr>
<tr>
<td>Patients with recurrence, n (%)</td>
<td>13 (26)</td>
<td>2 (8)</td>
<td>11 (44)</td>
<td></td>
</tr>
</tbody>
</table>

*For only patients alive at the time of this study. P < 0.05 is considered significant (Mann-Whitney test).
Van Allen et al.

mutations occurred in the cisplatin-sensitive tumors ($P<0.001$; Fisher exact test). ERCC2 remained significantly enriched in responders following false discovery analysis performed on genes in which the mutation frequency afforded adequate power ($q = 0.007$; Benjamini–Hochberg; Fig. 2B). Moreover, the enrichment for ERCC2 mutations in the responder group was significant when adjusted for differences in the overall mutation rate between responders and nonresponders ($P = 0.04$; binomial test). Toward this end, the median background mutation rate for ERCC2-mutant tumors (15.5 mutations/Mb) was significantly elevated compared with ERCC2 wild-type (WT) tumors (5.1 mutations/ Mb, $P = 0.01$; Mann–Whitney test; Supplementary Fig. S1B), consistent with a possible DNA-repair defect and prior reports (22).

The somatic ERCC2 mutation frequency in the responder cohort was also compared with two unselected bladder
cancer populations: 130 cases from The Cancer Genome Atlas (TCGA; ref. 21) and 99 cases from a Chinese patient cohort (ref. 22; Fig. 2C). When compared with these unselected populations, ERCC2 mutations were significantly enriched in the cisplatin responder cohort (36% of cases; \( P < 0.001 \); binomial test; Fig. 2C). ERCC2 mutation status does not seem to be prognostic, as it had no impact on overall survival in the TCGA cohort (\( P = 0.77 \); log-rank; Supplementary Fig. S3). To determine the relative abundance of somatic ERCC2 mutations in other tumor types, TCGA data from 19 tumor types (\( n = 4,429 \)) were queried (25). Somatic ERCC2 mutations were observed at low frequencies (<4%) in 11 other tumor types (Fig. 3A and B). All identified somatic ERCC2 mutations occurred at highly conserved amino acid positions within or immediately adjacent to the helicase domains (Fig. 3A and C and Supplementary Fig. S4). Similarly, germline ERCC2 mutations in

**Figure 3.** ERCC2 mutation mapping and distribution across tumor types. **A,** a stick plot of ERCC2 showing the locations of somatic mutations in the responders compared with ERCC2 mutations observed in two separate unselected bladder cancer exome cohorts. The ERCC2 mutations cluster within or near conserved helicase motifs. **B,** the somatic ERCC2 mutation frequency in multiple tumor types from TCGA. SCC, squamous cell carcinoma. **C,** structure of an archaeabacterial ERCC2 (PDB code, 3CRV) with mutations identified in the responder cohort mapped to their equivalent position. These locations are shown in the context of canonical germline ERCC2 mutations responsible for XP, XP/Cockayne syndrome (CS), and trichothiodystrophy (TTD).
patients with XP (complementation group D) and XP with combined Cockayne syndrome (XP/CS), two disorders characterized by NER function, clustered within helicase domains (Fig. 3C). Conversely, mutations causing trichothiodystrophy, a disease resulting from the alteration of ERCC2’s role in transcription, were distributed throughout the protein (26).

**ERCC2 Mutations Confer Increased Cisplatin Sensitivity In Vitro**

These observations raised the possibility that the identified mutations disrupt ERCC2 function and interfere with NER. To test this hypothesis, the first five of the identified ERCC2 mutants were stably expressed in an immortalized ERCC2-deficient cell line derived from an XP patient, and the cisplatin sensitivity profile of each cell line was measured (Supplementary Methods; Fig. 4A). Expression of WT ERCC2 rescued cisplatin sensitivity of the ERCC2-deficient cell line, whereas none of the ERCC2 mutants rescued cisplatin sensitivity (Fig. 4B). The IC50 for the ERCC2-WT–compemented cell line was significantly higher than that for the ERCC2-deficient parent cell line (P < 0.0001; ANOVA), whereas the IC50 for each ERCC2-mutant–complemented cell line was not significantly different from the parent ERCC2-deficient parent cell line (Fig. 4C). Similarly, the IC50 for the ERCC2-WT
cell line was significantly higher than that for the ERCC2-deficient and mutant cell lines ($P < 0.0001$; ANOVA).

The NER pathway repairs DNA lesions other than cisplatin adducts, so we also tested the effect of the identified ERCC2 mutations on NER-mediated repair of UV-induced DNA damage. WT and mutant ERCC2-complemented cell lines were exposed to increasing doses of UV irradiation, and clonogenic survival was measured (Fig. 5A–C). Whereas the ERCC2-WT–complemented cell line rescued UV sensitivity, the UV sensitivities of the ERCC2-mutant–complemented cell lines were not significantly different from that of the ERCC2-deficient parent cell line. Taken together, these experiments...
suggest that the observed ERCC2 mutations result in loss of normal NER capacity. Because the overall mutation rate was higher in ERCC2-mutated tumors, we hypothesized that ERCC2 mutations may be broadly contributing to genomic instability. Thus, we measured rates of chromosomal aberrations in WT and mutant ERCC2–complemented cell lines before and after cisplatin treatment. In the absence of cisplatin, background rates of chromosomal aberrations were slightly lower in the ERCC2-WT cell line than in the ERCC2-deficient line or the cell lines expressing mutant ERCC2 (P = 0.03; ANOVA), whereas expression of the ERCC2 mutants resulted in no rescue of chromosomal stability (P > 0.5; Fig. 6D). These data suggest that the responder-associated ERCC2 mutations may contribute to overall genomic instability in these tumors.

**Other DNA Repair Gene Alterations**

Finally, we sought to determine whether other DNA repair genes might undergo recurrent mutations in cisplatin-sensitive tumors. No significantly recurrent mutations were observed in other NER or homologous repair genes in responders compared with nonresponders. However, in two responder tumors that did not have ERCC2 mutations, somatic nonsense (truncating) mutations were detected in the homologous recombination DNA repair genes BRCA1 and BRCA2 (Supplementary Table S2). There were no nonsynonymous BRCA1 or BRCA2 mutations in the nonresponders (Supplementary Table S2). These results are consistent with the known sensitivity of BRCA1/2-mutant tumors (e.g., BRCA1/2-mutant breast or ovarian cancers) to platinum-containing regimens (27). Whereas somatic ERCC2 mutations were the only DNA repair gene mutations enriched in the responders, singleton missense mutations of uncertain significance were observed in DNA damage response genes in both responders and nonresponders, and are of unknown functional relevance.

**DISCUSSION**

In bladder cancer, the clinical benefit of neoadjuvant chemotherapy is most apparent when pathologic downstaging to pT0 or pTis is achieved at surgical resection following...
cisplatin-based chemotherapy. However, the lack of a predictive biomarker for clinical benefit from neoadjuvant cisplatin-based chemotherapy has limited the use of this approach in the clinical community due to toxicity concerns. Using an extreme phenotype analysis, we have identified an association between somatic ERCC2 mutations and pathologic complete response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive urothelial carcinoma. Although ERCC2 mutations occur in approximately 12% of unselected cases, 36% of cisplatin-based chemotherapy responders in our cohort harbored somatic ERCC2 nonsynonymous mutations. Moreover, all ERCC2-mutant tumors responded to neoadjuvant chemotherapy. The NER pathway is a highly conserved DNA repair system that identifies and repairs bulky DNA adducts arising from genotoxic agents such as cisplatin. The NER helicase ERCC2 unwinds duplex DNA near the damage site through the coordinated action of two conserved helicase domains. All ERCC2 mutations identified in this study occurred at conserved positions within or adjacent to these helicase domains, and the identified mutants all failed to complement cisplatin or UV sensitivity of an ERCC2-deficient cell line. Together, these data suggest that the mutations result in loss of normal ERCC2 function, leading to increased tumor cell sensitivity to DNA-damaging agents such as cisplatin.

Interestingly, in seven (78%) of the ERCC2-mutant cases, the ERCC2 mutation allelic fraction was <0.5 (Supplementary Table S2), suggesting that WT ERCC2 remains present at one allele. Therefore, the cisplatin sensitivity phenotype may result from a haploinsufficient or dominant-negative effect of a heterozygous ERCC2 mutation, rather than as a result of biallelic inactivating mutations (as in the traditional “two-hit” tumor suppressor model). The driving force for heterozygous mutation of ERCC2 is unknown; however, the prevalence of ERCC2 mutations in this study and other cohorts (such as the TCGA) suggests that loss of normal ERCC2 function may provide a selective advantage for tumors. Partial loss of DNA repair fidelity could aid tumor growth by decreasing repair-associated delays in cell-cycle progression. In addition, decreased NER capacity may result in higher rates of error-prone repair or large-scale genomic changes that further drive tumor growth. Despite providing a potential growth advantage, mutation of one ERCC2 allele may render tumor cells susceptible to a DNA-damaging agent such as cisplatin if inadequate levels of WT ERCC2 are present to support NER (i.e., haploinsufficiency). Alternatively, the mutated version of ERCC2 may bind, but not efficiently repair, damaged DNA, thereby preventing repair by an alternative DNA-repair pathway and leading to a dominant-negative phenotype, as has been described for mutants of the yeast ERCC2 homolog Rad3 (28). Further studies are necessary to explore the effects of ERCC2 loss on tumor growth, and the mechanism by which the identified ERCC2 mutations confer changes in tumor NER capacity.

One possible explanation for the findings observed in this study is that somatic ERCC2 mutation is associated with good prognosis or smaller tumors. However, this is not supported by the survival data from the TCGA bladder cancer cohort, which excluded patients who received neoadjuvant chemotherapy. No difference in overall survival was observed on the basis of somatic ERCC2 mutation status (Supplementary Fig. S3). In the extreme response cohort reported here, patients were generally noted to have obvious disease left behind after initial transurethral resection based on operative reports and imaging, making the findings unlikely to be related to complete transurethral resection.

Although these data should not yet be used to justify avoiding cisplatin-based treatment in ERCC2 WT patients, our findings raise the possibility that somatic ERCC2 mutation status may provide a genetic means to select patients most likely to benefit from cisplatin-based chemotherapy, while directing other patients toward alternative therapeutic approaches. Of note, our study focused specifically on somatic mutations that are exclusively in the tumor, and not germline single-nucleotide polymorphisms in ERCC2 or other genes. Thus, this approach is distinct from genomewide association studies that have examined germline ERCC1 or ERCC2 polymorphisms and their mixed impact on cisplatin sensitivity (29). Broadly, these findings will require independent clinical validation in prospective trials to establish the clinical predictive power of somatic ERCC2 mutation status for cisplatin response.

It is possible that some nonresponding urothelial tumors will harbor somatic ERCC2 mutations in larger cohorts; if observed, examination of the post–chemotherapy-resistant tumor would be critical to understanding whether tumor heterogeneity played a role in resistance. The patients analyzed in this extreme phenotype analysis were treated with combination cisplatin-based chemotherapy regimens containing non-cisplatin agents; however, cisplatin was the only agent common to all regimens. Because half of patients with bladder cancer are not candidates for cisplatin-based chemotherapy due to preexisting comorbidities, less toxic carboplatin-based neoadjuvant therapies may warrant study for non–cisplatin-eligible patients with ERCC2-mutant tumors. To date, exceptional response genomics studies have informed genomic mechanisms of response to targeted therapies, such as response to everolimus in multiple disease contexts (30, 31). However, published studies have been limited to individual case reports due to the rarity of such events with targeted therapies. This study represents a new approach for studying extraordinary responses to commonly used cytotoxic chemotherapies using a case-control design, which may be applied to other therapeutic settings in which a significant minority of patients achieve exceptional response (e.g., neoadjuvant chemotherapies in other clinical settings). Toward that end, a majority of responder cases in our cohort had no recurrent genomic determinant of cisplatin response. It is possible that alterations in DNA repair genes not readily detectable with WES (e.g., epigenetic, expression-based) may mediate cisplatin sensitivity in these cases.

In conclusion, this work provides new insights into the relationship between somatic genetic alterations and clinical response to cisplatin-based chemotherapy in urothelial carcinoma. If further validated, these results may inform therapeutic decision-making, novel therapeutic development, and clinical trial designs for urothelial carcinoma and possibly other ERCC2-mutated tumors. Finally, these results show that somatic genomic alterations may reveal the mechanistic
underpinnings of antitumor response to conventional cytotoxic chemotherapy.

METHODS

Patients and Samples

Patients with muscle-invasive or locally advanced urothelial carcinoma, extreme responses to chemotherapy (defined as no residual invasive carcinoma at cystectomy or presence of persistent muscle-invasive or extravesical disease at cystectomy), and available prechemotherapy tumor tissue who were enrolled on Institutional Review Board (IRB)-approved tissue acquisition and DNA-sequencing protocols were identified (Dana-Farber protocols 02-021 and 11-334; Memorial Sloan Kettering Cancer Center protocols 89-076 and 09-025). All patients provided written informed consent for genomic testing used for this study. Specimens were evaluated by genitourinary pathologists (J.A. Barletta/S. Signoretti—DFCI cohort, and H. Al-Ahmadie—MSKCC cohort) to identify tumor-bearing areas for DNA extraction. The minimum percentage of neoplastic cellularity for regions of tumor tissue was 60%. Study specimens of frozen or formalin-fixed, paraffin-embedded (FFPE) tissue sections were identified at the Dana-Farber Cancer Institute (DFCI) and Memorial Sloan Kettering Cancer Center (MSKCC). Germline DNA was extracted from either peripheral blood mononuclear cells or histologically normal nonurothelial tissue. Information about the source of germline DNA is available in Supplementary Table S1.

WES and Statistical Analysis

DNA extraction and exome sequencing Slides were cut from FFPE or frozen tissue blocks and examined by a board-certified pathologist to select high-density cancer foci and ensure high purity of cancer DNA. Biopsy cores were taken from the corresponding tissue block for DNA extraction. DNA was extracted using Qiagen’s QIAamp DNA FFPE Tissue Kit Quantitation Reagent (Invitrogen). DNA was stored at −20°C. Whole exome–capture libraries were constructed from 100 ng of DNA from tumor and normal tissue after sample shearing, end repair, and phosphorylation and ligation to barcoded sequencing adaptors. Ligated DNA was size-selected for lengths between 200 and 350 bp and subjected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent Technologies). The sample was multiplexed and sequenced using Illumina HiSeq technology for a mean target exome coverage of 121× for the tumors and 130× for germline samples. Four cases did not complete the exome-sequencing process due to sequencing process failure. All BAM files generated for this study will be deposited in the database of Genotypes and Phenotypes (dbGaP, phs000771.v1.p1).

Sequence data processing Exome sequence data processing and analysis were performed using pipelines at the Broad Institute. A BAM file aligned to the hg19 human genome build was produced using Illumina sequencing reads for the tumor and normal sample and the Picard pipeline. BAM files were uploaded into the Firehose infrastructure (32), which managed intermediate analysis files executed by analysis pipelines. All BAM files will be uploaded to dbGaP (phs000771.v1.p1).

Sequencing quality control Sequencing data were incorporated into quality-control modules in Firehose to compare the tumor and normal genotypes and ensure concordance between samples. Cross-contamination between samples from other individuals sequenced in the same flow cell was monitored with the ContEst algorithm (33). Samples with >4% contamination were excluded (n = 4).

Alteration identification and annotation The MuTect algorithm (34) was applied to identify somatic single-nucleotide variants in targeted exons. Indelocator was applied to identify small insertions or deletions (35). Gene-level coverage was determined with the DepthOfCoverage in the Genome Analysis Tool Kit (36). Alterations were annotated using Oncotator (37). Power calculations for coverage were determined using the MuTect coverage file, which requires a minimum of 14× coverage in the tumor. Samples with median allelic fractions less than 0.05 and insufficient DNA for orthogonal validation with Fluidigm Access Array were excluded (n = 1).

Alteration significance MutSigCV (23) was applied to the aggregate cohort of 50 cases to determine statistically altered genes in the cohort. Alterations from all nominated significant genes from MutSigCV were manually reviewed in the Integrated Genomics Viewer (IGV; refs. 38, 39). Alterations that were invalid based on IGV review (as a result of misalignment artifacts viewable in IGV) were subsequently excluded from the final results, which resulted in the exclusion of TGFBR1 and DEPDC4 from the final result (Supplementary Table S3).

Selective gene enrichment analysis All somatic mutations and short insertion/deletions were aggregated for the cohort and split between responders and nonresponders. Alterations with coverage at the tumor site of ≥20× and an allelic fraction of ≥0.1 were considered for further analyses. Missense, nonsense, and splice-site mutations, along with short insertion/deletions, were then assigned a damaging score (range, 0–1) following previously reported methods (40). Missense mutations were scored using the Polyphen2 score (41) for the amino acid substitution. Missense mutations without available Polyphen2 scores (due to mapping errors or dinucleotide status) were listed as “unavailable” in Supplementary Table S5 and excluded. Nonsense mutations, splice-site mutations, and short insertion/deletions were assigned a damaging score of 1. Damaging scores are listed in Supplementary Table S5. Alterations with a damaging score of 2.05 were then tabulated for occurrence in responders and nonresponders. An altered gene would be considered only on the basis of the tumor patient. The Fisher exact test was performed to compare between cohorts to derive a P value for each gene. Because a minimum of six alterations were required to observe a P value of ≤0.01, only genes with 26 alterations in the cohort (thereby representing >10% of the cohort and of highest potential clinical significance) were considered for multiple hypothesis testing. These results are summarized in Supplementary Table S6 and Fig. 2A. The ERCC2 mutation frequency in the responders was compared with the unscreened TCGA (21) and Guo and colleagues (22) cohorts with a binomial test. Results from this analysis are made available in Fig. 2C. Comparison of ERCC2 mutation distribution between responders and nonresponders adjusted for elevated mutation rate in the responders was performed with the binomial test conditional on observing nine mutations and using the estimated ratio of mutation rates between responders and nonresponders as the expected frequency of ERCC2 mutations in responders under the null hypothesis [e.g., for ERCC2, binomial test (x = 9; n = 9, P = Mutation_Rate_Responders/Mutation_Rate_Nonresponders, alternative = “greater”). All statistical calculations were performed using the R statistical package.

Mutation Validation

Orthogonal validation of selected mutations and short insertion/deletions (those presented in this article, including ERCC2) was performed using the Fluidigm Access Array. Of 50 cases, 35 had sufficient DNA to generate sufficient read depth for analysis. A total of 85 candidate targets were submitted to Fluidigm for single-plex PCR primer assay design. This resulted in the design of 65 assays covering all 85 targets. Assay amplicons ranged from 163 to 199 bp in size, with an average of 183 bp. All available samples were run on the Access Array system (Fluidigm) using three 48.48 Access Array IFC chips following the manufacturer’s recommendations using the
**ERCC2 and Cisplatin Sensitivity in Urothelial Carcinoma**

"4-Primer Amplicon Tagging protocol" for Access Array (Fluidigm; P/N 100-3770). Rev. C1), with the exception that Access Array IFC chips were loaded and harvested using a Bravo Automated Liquid Handling Platform (Agilent Technologies), following the manufacturer’s recommendations. Resulting amplicons containing sample-specific barcodes and Illumina adapter sequences were pooled and sequenced on a MiSeq sequencer (Illumina) with two runs of 150 base paired-end reads (V2 sequencing chemistry), using custom Fluidigm sequencing primers following the manufacturer’s recommendations (Fluidigm). All sites were manually reviewed in IGV to determine the presence or absence of nonreference reads. Details about validation results for ERCC2 and additional variants are given in Supplementary Table S2. Variants in which there was inadequate sample for validation or insufficient sequencing reads in the validation data to interpret manually in IGV were listed as “unavailable.”

**Cloning and Cell Lines**

A site-directed PCR mutagenesis/_bp/ (attB-attP) recombination method (42) was used to generate WT and mutant ERCC2 open reading frames (ORF). For each mutant, PCR products were generated such that fragments overlap at the region of the desired muta-
tion. The fragments were then introduced into the pDONR vector through the BP reaction. The BP reaction mixture was transformed into E.coli coli and recombined to generate a pENTR vector. The pENTR vector was then used to perform the LR (attL-attR) reaction to create an expression plasmid.

The expression plasmids harboring WT ERCC2, GFP (negative control), or mutant ERCC2 constructs were expanded in E. coli TOP10 cells (Invitrogen) and purified using an anion exchange kit (Qiagen). Lentiviruses were propagated in 293T cells by cotransfec-
tion of the expression plasmid with plasmids encoding viral packaging and envelope proteins. Unless otherwise noted, all human cell lines were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Sigma) and 1% l-glutamine and grown at 37°C and 5% CO2. The 293T cell supernatants containing virus were collected after 48 hours, filtered twice (0.45-μm syringe filter; Millipore), then added to TOP10 cells (Invitrogen) and purified using an anion exchange kit.

**Cisplatin Sensitivity Assays**

Cells were transferred to 96-well plates at a density of 500 cells per well. Six hours later, cisplatin (Sigma) was serially diluted in media and added to the wells. After 96 hours, CellTiterGlo reagent (Promega) was added to the wells, and the plates were scanned using a luminescence microplate reader (BioTek). Survival at each cisplatin concentration was plotted as a percentage of the survival in cisplatin-free media. Each data point on the graph represents the average of three independent measurements, and the error bars represent the standard deviation.

**UV Clonogenic Survival Assays**

Cells were seeded in 6-well plates (Nunc) at a density of 1,500 cells per well. The following day, the cells were washed once with PBS and then exposed to increasing UV doses using a UV-B irradiator (Strata-
gene). Medium was replaced, and the cells were allowed to grow for 9 days. On day 10, cells were fixed using a 1.5 acetic acid/methanol solution for 20 minutes at room temperature. Cells were then stained for 45 minutes using 1% crystal violet in methanol solution. Plates were rinsed vigorously with water, allowed to dry, and colonies were then manually counted. The number of colonies present at each UV dose was plotted as a ratio of the number of colonies present in mock-irradiated wells. Each data point represents the average of three independent measurements, and the error bars represent the standard deviation.

**Chromosomal Breakage Analysis**

Approximately 1 × 106 cells were seeded per 10-cm dish. After 24 hours, 400 mmol/L of cisplatin was added, and cells were allowed to grow for an additional 48 hours. Cells were exposed to colcemid for 2 hours, harvested using 0.075 mol/L KCl, and fixed in 3:1 methanol/acetic acid. Slides were stained with Wright's stain, and 25 to 50 metaphases were analyzed for chromosomal aberrations (chromosome or chromatid breaks, rings, translocations, deletions, fragments/double minute chromosomes, trir- or quadraradials, del- or transcentrics, and premature chromatid separation).

**Immunoblots**

Frozen cell pellets were thawed and resuspended in RIPA buffer [50 mmol/L TRIS (pH 7.3), 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100, 0.5% Na-deoxycholate, and 0.1% SDS] supplemented with complete protease inhibitor (Roche), NaVO4, and NaF. The cell suspensions were centrifuged, and total protein concentration of the supernatant was determined by colorimetry (Bio-Rad). Samples were boiled with loading buffer (Bio-Rad) and electrophoresed in a 3% to 8% gradient TRIS-acetate gel (Life Technologies). Resolved proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore) at 90 V for 2 hours at 4°C. The membrane was blocked for 1 hour in blocking solution (5% milk in TRIS-buffered saline-T) and incubated with primary antibody in blocking solution at 4°C overnight (mouse ERCC2, Abcam; rabbit β-actin, Cell Signaling Technology). The following day, the membrane was rinsed and incubated for 1 hour with peroxidase-conjugated secondary antibody in blocking solution (anti-mouse and anti-rabbit; Cell Signaling Tech-
nology) and rinsed. Enhanced chemiluminescent substrate solution (PerkinElmer) was added and signal was detected by film exposure (GE Healthcare).

**Disclosure of Potential Conflicts of Interest**

E.M. Van Allen has ownership interest in a patent (pending). N. Wagle has ownership interest in and is a consultant/advisory board member for Foundation Medicine. D.F. Bajorin is a consultant/advisory board member for Bristol-Myers Squibb. L.A. Garraway reports receiving a commercial research grant from Novartis, has ownership interest in Foundation Medicine, and is a consultant/advisory board member for Novartis, Foundation Medicine, and Boehringer Ingelheim. J.E. Rosenberg has ownership interest in a patent (pending). No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.M. Van Allen, P. Kim, J. Sfakianos, I. Garcia-Grossman, R. Bambury, S. Bahl, D. Farlow, A. Qu, T.K. Choueiri, J.E. Rosenberg


Other (project management): N. Gupta

Acknowledgments

The authors thank the patients for contributing tissue for research.

In addition, the authors thank Dr. Kenneth Shaw, Dr. Jean C. Zenklusen, and The Cancer Genome Atlas for allowing pertinent ERCC2 results to be incorporated into their analyses. The authors also thank Dr. Joaquim Bellmunt for thoughtful feedback and clinical review of cases, the Broad Genomics Platform for sequencing and validation activities, and Lisa Moreau for help with chromosomal studies.

Grant Support

This study was supported by the Dana-Farber Leadership Council (to E.M. Van Allen), the American Cancer Society (to E.M. Van Allen), the Conquer Cancer Foundation (to E.M. Van Allen and K.W. Mouw), the NIH/National Human Genome Research Institute (U54HG003067, to L.A. Garraway and S. Gabriel), Cycle for Survival (to G. Iyer, I. Ostrovnya, and B.H. Bochner), the Geoffrey Beene Cancer Research Center (to J.E. Rosenberg, D.B. Solit, H. Al-Ahmadie, and I. Ostrovnya), and the Starr Cancer Consortium (to J.E. Rosenberg. E.M. Van Allen, G. Iyer, L.A. Garraway, I. Ostrovnya, and H. Al-Ahmadie).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 13, 2014; revised July 24, 2014; accepted July 28, 2014; published OnlineFirst August 5, 2014.

REFERENCES


Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Eliezer M. Van Allen, Kent W. Mouw, Philip Kim, et al.

Cancer Discovery 2014;4:1140-1153. Published OnlineFirst August 5, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-14-0623

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2014/08/08/2159-8290.CD-14-0623.DC1

Cited articles
This article cites 39 articles, 15 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/4/10/1140.full#ref-list-1

Citing articles
This article has been cited by 22 HighWire-hosted articles. Access the articles at:
http://cancerdiscovery.aacrjournals.org/content/4/10/1140.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.